Regulatory
Nucala receives FDA approval for COPD (opens source in a new tab)GSK · 2025
Nucala · COPD
Keep your working files current between reviews.
Upload or create files in a Maven project. Maven identifies material changes and applies source-linked edits to the files you select, ready to review and download.
Keep the work moving as the evidence changes.
Follow sources
Regulatory & HTA decisions
Trials, literature & congresses
Company news & financial filings
Product, HCP & advocacy sites
Trade press & industry news
Assess material changes
Your scope, questions
and working files
and working files
Maven
Evidence linked across drugs, trials and companies.
Update selected files
A signal with contextWhat changed and why it matters
Your maintained project files
PPowerPointXExcelWWord
Inspect the change and its sourceSee more of the market as it develops.
Follow company sites, trials, publications, regulatory bodies, and local access decisions across global sources.
Sources across the world
Source locations Highlighted: Companies
Signal detection
Clinical evidence
MATINEE results published for mepolizumab in COPD (opens source in a new tab)NEJM · 1 May 2025
Mepolizumab · COPD
Market access
Singapore publishes funding criteria for atopic dermatitis therapies (opens source in a new tab)ACE · 2 Jan 2024
Abrocitinib · Atopic dermatitis
Assess new evidence against your team’s priorities.
Define the assets, markets, questions, and changes that matter to your team. Maven assesses new evidence against that scope and explains why a finding affects your work.
Trial amendment
HTA guidance
Company update
Your team’s priorities
Does DAPA-MI still test the outcome in our thesis?
Matched to your watchExample signal
DAPA-MI changes its primary endpoint.
Previous primary endpointCV death or heart-failure hospitalization
Revised primary endpoint7-component cardiometabolic composite
The original cardiovascular endpoint is now secondary. Reassess the thesis against both outcomes.
View evidence
The registry records a February 2023 amendment prompted by a lower-than-expected blinded event rate. The primary endpoint became a hierarchical cardiometabolic composite assessed using a win-ratio analysis. The original cardiovascular endpoint became secondary. The registry results were published on 7 July 2024.
EU trial register · Amendment 23 Feb 2023Update the same working files as the assessment changes.
Maven carries clinical findings and access conditions into the tracker, briefing, and presentation, with sources attached to each edit.
Funding conditions narrow the eligible population.
access_tracker.xlsx
Home InsertData
AB
1MarketEligibility
2SingaporeEligibility not recorded.Abrocitinib: prior systemic-therapy criteria apply.¹
Access tracker Sources
market_brief.docx
Home LayoutReferences
Access implications
market_review.pptx
Home DesignReview
Sourced edits applied to 3 files
Review edits and download your maintained files.
Maven can apply edits automatically, with revision history and rollback. Files remain in your Maven project, available to download as Word, Excel, or PowerPoint.
Revision history
Illustrative examplemarket_brief.docxVersion 2
Access implications
Bring live intelligence into the tools you use.
Connect AI assistants through MCP and reusable skills, or query structured data and retrieve monitoring findings through the API, with webhook notifications for new signals.
Explore AI integrations →